Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Cannabidiol (CBD) is a phytocannabinoid, one of 113 identified cannabinoids in Cannabis, along with tetrahydrocannabinol (THC), and accounts for up to 40% of the plant's extract. Medically, it is an anticonvulsant used to treat two rare forms of childhood epilepsy. It was discovered in 1940. Clinical research on CBD has included studies related to the treatment of anxiety, addiction, psychosis, movement disorders, and pain, but there is insufficient high-quality evidence that CBD is effective for these conditions. CBD is sold as a herbal dietary supplement and promoted with unproven claims of particular therapeutic effects.
Read the full article on WikipediaSevere myoclonic epilepsy in infancy (Dravet syndrome) Clinical criteria: Patient must have (as an initiating patient)/have had (as a continuing patient), generalised tonic-clonic seizures or generalised clonic seizures that are not adequately controlled with at least two other antiseizure medications, AND The treatment must be as adjunctive therapy to at least two other antiseizure medications. Treatment criteria: Must be treated by a neurologist if treatment is being initiated; OR Must be treated by a neurologist if treatment is being continued or re-initiated; OR Must be treated by a paediatrician in consultation with a neurologist if treatment is being continued; OR Must be treated by a general practitioner in consultation with a neurologist if treatment is being continued.
“In vitro, cannabidiol has low affinity for, and acts as a negative allosteric modulator of the CB1 cannabinoid receptor”
“18–32 hours”
Working under the parallel aged-care framework? Aged-care equivalent →
Seizures of the Lennox-Gastaut syndrome Clinical criteria: Patient must have a diagnosis of Lennox-Gastaut syndrome; the diagnosis should be confirmed by an electroencephalogram (EEG) where possible, AND Patient must have (as an initiating patient)/have had (as a continuing patient) more than one type of seizure that is not adequately controlled with at least two other antiseizure medications prior to initiating treatment with this medicine, AND The treatment must be as adjunctive therapy to other antiseizure medication. Treatment criteria: Must be treated by a prescriber who is either: (i) a neurologist, (ii) a paediatrician if treatment is being initiated; OR Must be treated by a prescriber who is either: (i) a neurologist, (ii) a paediatrician if treatment is being continued or re-initiated; OR Must be treated by a general practitioner in consultation with either: (i) a neurologist, (ii) a paediatrician if treatment is being continued. Confirmation of eligibility for treatment with diagnostic reports must be documented in the patient's medical records.